Questions

176. Deputy Colm Burke asked the Minister for Health to outline the number of new medicines which were submitted to the NCPE in each year between 2015 and 2025; and the number of these new medicines that were non-oncology orphan medicinal products, in tabular form; and if she will make a statement on the matter. [60301/25]

177. Deputy Colm Burke asked the Minister for Health to outline the number of non-oncology orphan medicinal products which were referred to the HSE Drugs Group by the NCPE in each year between 2015 and 2025; and to provide a breakdown of the number of successful, negative and pending reimbursement decisions for such products, in tabular form; and if she will make a statement on the matter. [60302/25]

178. Deputy Colm Burke asked the Minister for Health the average length of time taken for non-oncology orphan medicines to receive a final reimbursement decision from the HSE Drugs Group after the submission of a pricing application by a manufacturer, in tabular form; and if she will make a statement on the matter. [60303/25]

179. Deputy Colm Burke asked the Minister for Health the number of non-oncology orphan medicines which were approved by the HSE drugs group in each year from 2015 to 2025 and which did not satisfy the QALY threshold for cost-effectiveness, in tabular form; and if she will make a statement on the matter. [60304/25]

180. Deputy Colm Burke asked the Minister for Health the number of new medicines which were submitted to the NCPE in each year between 2015 and 2025; to provide a breakdown of the number of these new medicines that were non-oncology orphan medicinal products, in tabular form; and if she will make a statement on the matter. [60305/25]

181. Deputy Colm Burke asked the Minister for Health the number of non-oncology orphan medicinal products which were referred to the HSE drugs group by the NCPE in each year between 2015 and 2025; to provide a breakdown of the number of successful, negative and pending reimbursement decisions for such products, in tabular form; and if she will make a statement on the matter. [60306/25]

182. Deputy Colm Burke asked the Minister for Health the average length of time taken for non-oncology orphan medicines to receive a final reimbursement decision from the HSE drugs group after the submission of a pricing application by a manufacturer, in tabular form; and if she will make a statement on the matter. [60307/25]

246. Deputy Colm Burke asked the Minister for Enterprise, Tourism and Employment if he is concerned by delays within Ireland’s system of reimbursement of new medicines; his views on whether this is an competitiveness issue; if he will raise delays with the Minister for Health; and if he will make a statement on the matter. [49733/25]

1294. Deputy Colm Burke asked the Minister for Health if consideration would be given to placing the drug known as Mounjaro under the HSE reimbursable items list as a treatment for obesity; and if she will make a statement on the matter. [48667/25]

2136. Deputy Colm Burke asked the Minister for Health if she will confirm that a product (details supplied) will be placed under the Health Service Executive reimbursable items list so that persons under this scheme can avail of a 2.4mg maximum dosage compared to another product (details supplied) where the maximum dose is 1mg and is only reimbursed for the treatment of diabetes; and if she will make a statement on t…

197. Deputy Colm Burke asked the Minister for Health if she will prioritise the Programme for Government commitment to investigate early access schemes for orphan medicines; and if she will make a statement on the matter. [34701/25]

1467. Deputy Colm Burke asked the Minister for Health if she is concerned by the latest data from the EFPIA Patient Wait Indicator 2024, indicating an average wait time of 645 days for access to new medicines in Ireland, which constitutes a further disimprovement on last year's figures; to outline what plans are underway to improve the structures and speed of the system, in line with the Programme for Government comm…

1468. Deputy Colm Burke asked the Minister for Health if the 34 new whole-time equivalent positions for the agencies involved in the HSE's medicines pricing and reimbursement system, as initially prescribed in February 2023 by the then-Minister for Health, have now been successfully filled; whether they have commenced their engagement; and if she will make a statement on the matter. [29792/25]

1470. Deputy Colm Burke asked the Minister for Health her views on the findings of a report (details supplied) in relation to the development of a system of transferable exclusivity vouchers; whether she is supportive of the introduction of such a system at Irish and EU level; and if she will make a statement on the matter. [29794/25]

185. Deputy Colm Burke asked the Minister for Health if she will consider reducing the threshold of the drugs payment scheme to €72 per month, as per the 2017 Sláintecare report; and if she will make a statement on the matter. [9954/25]

236. Deputy Colm Burke asked the Minister for Health if any further consultation has taken place between her Department and the Health Products Regulatory Authority on the matter of uromune becoming available for the treatment of recurrent urinary tract infections, given that it is becoming more readily available as a treatment across the world; and if she will make a statement on the matter. [3744/25]

1261. Deputy Colm Burke asked the Minister for Health if consideration could be given to approving all patients with type 1 diabetes mellitus to qualify for reimbursement for continuous glucose monitoring (CGM) under the community drug schemes, as many type 1 diabetes patients require CGM but are being refused reimbursement as they have not required insulin from the outset of their disease; and if she will make a sta…